JPMorgan analyst Jessica Fye views shares of Amarin as "more interesting" following the recent pullback. Vascepa is poised to achieve blockbuster status "and then some," ramping to $5B global 2028 revenue, says the analyst, who sees a "valuation opportunity" following the recent share pullback assuming Amarin's intellectual property holds. With encouraging script trends and an uneventful Q4 update, investor focus remains squarely on the upcoming outcome of Amarin's patent litigation with a decision expected in late March, Fye tells investors in a post-earnings research note. While the stock has been weak ahead of the court ruling, the analyst believes Amarin is likely to prevail, which she thinks would trigger a return to prior share levels. She does, however, keeps a Neutral rating on the stock with a $22 price target. Amarin in premarket trading is down 35c to $17.15.